Article Type : Short commentary
Authors : Wood M, Ebe K and Bando H
Keywords : Type 1 diabetes (T1D); Low-carbohydrate diet (LCD); Multiple daily injection (MDI); Self-monitoring of blood glucose (SMBG); Glycemic control; Diabetic complications
Dr. Richard K. Bernstein, diagnosed with type 1 diabetes (T1D) at age 12, revolutionized diabetes management through his pioneering low-carbohydrate approach to achieving normal blood glucose levels. Initially an engineer, Bernstein’s personal struggle with diabetic complications led him to self-monitor blood glucose using early devices and experiment with low-carbohydrate diets and insulin adjustments. His findings, which demonstrated the reversal of complications through tight glycemic control, faced rejection from medical journals due to his lack of credentials. Undeterred, Bernstein pursued medical training at age 45, became an endocrinologist, and established a practice focused on low-carbohydrate diabetes management. His influential books, including Dr. Bernstein’s Diabetes Solution, and advocacy for frequent glucose monitoring and multiple daily insulin injections shaped modern diabetes care, influencing the Diabetes Control and Complications Trial (DCCT). Bernstein’s legacy underscores a paradigm shift toward proactive, individualized diabetes care, improving outcomes for individuals with diabetes
A
Tribute to Dr. Richard K. Bernstein: Pioneering Normal Blood Sugars through
Low-Carbohydrate Diabetes Management
Dr. Richard K. Bernstein was born on
June 17, 1934, in Brooklyn, New York. He was diagnosed with T1D at age 12,
beginning his personal journey with the disease. He graduated from Columbia
University with a BA (1954) and BS (1955) (Figure 1). Thereafter, he worked as
an industrial-management engineer and later as director of research,
development, and marketing for Clay Adams, a medical equipment manufacturer.
During this time, Bernstein diligently followed the dogma of the time, but
still suffered from numerous diabetic complications and frequent hypoglycemia
episodes [1].
Bernstein began searching for literature on how to reverse diabetic complications and came across a study in animals that achieved such a feat by normalizing blood glucose. He was dismissed by his physician at the time due to the lack of human studies [1]. In October 1969, Bernstein found an advertisement for the Ames Reflectance Meter (ARM), a device that could help his situation, in the magazine Lab World. He obtained the 3-pound ARM (intended for hospital use) through his wife, a psychiatrist [1]. Utilizing his training in mathematics and engineering, Bernstein began self-monitoring blood glucose and discovered his highest blood sugars were after eating carbohydrate-containing foods. He would frequently have a tuna, mayo, and peanut butter on date nut bread sandwich for lunch [2]. Eating tuna, mayo, and a salad in place of the bread and peanut butter stabilized his blood sugars. He started experimenting with diet and insulin adjustments to achieve normal blood sugar levels, reversing many of his diabetes-related complications. Bernstein found success in doing the opposite of what was in fashion in that era and confirmed that normalizing blood glucose in a human could prevent or improve diabetic complications.
In the early 1970s, Dr. Bernstein had
incorporated the Law of Small Numbers into his protocol, advocating smaller
insulin doses and low-carbohydrate intake to minimize blood sugar fluctuations
and reduce the risk of hypoglycemia. Bernstein simply stated, "Big input
makes for big mistakes, small input makes for small mistakes," a phrase he
attributes to his friend Kanji Ishikawa, whom he describes as the oldest
surviving type 1 diabetic in Japan [3].
Bernstein submitted his protocol to
numerous medical journals, which rejected it due to his lack of medical
credentials [4]. One such rejection described Bernstein as a “spartan and a
paragon,” implying that it would be unlikely to find anyone to follow his rigid
protocol (Figure 2). Bernstein had also been keeping up-to-date with diabetes
research at the time and was disappointed to see article after article claim
there was no way to normalize blood sugar. With free supplies from Ames,
Bernstein was able to initiate two studies in the New York City area by 1977 [1].
The studies focused on diabetic patients and succeeded in reversing early
complications through blood glucose self-monitoring and intensive management,
consistent with Bernstein’s own experience.
These experiences stimulated the trained engineer to pursue a career in medicine because as he said, “I couldn’t beat ’em, so I had to join ’em” [1]. Bernstein enrolled at the Albert Einstein College of Medicine in 1979 at age 45 to gain medical credentials and legitimize his research. He graduated in 1982 as an endocrinologist and in 1983 opened a private medical practice in Mamaroneck, New York, dedicated to treating diabetes and prediabetes using his low-carbohydrate approach.
In 1980, Bernstein published an
account of his personal experience [5]. “Diabetes: The Glucograf Method for
Normalizing Blood Sugar”, one of his early works outlining his blood sugar
management techniques, was published in 1981. This book lays the groundwork for
Bernstein’s approach to insulin dosing, outlining his method of frequent blood
glucose self-monitoring and multiple daily insulin injections (MDI) to maintain
near-normal blood sugar levels. Although analog insulins did not yet exist,
Bernstein would address the need to cover both basal and bolus (e.g., meal)
insulin requirements.
Bernstein’s self-experimentation and
advocacy for frequent blood glucose monitoring were instrumental in convincing
the diabetes community of its value. The National Institutes of Health decided
to fund the Diabetes Control and Complications Trial (DCCT) in 1982 [6]. The
DCCT, launched in 1983, assessed whether intensive frequent glucose monitoring
and MDI of basal and bolus insulin could prevent or delay complications in T1D
[7]. While the DCCT focused solely on intensive insulin therapy, adjusting
insulin doses based on frequent blood sugar monitoring, it unfortunately did
not incorporate Bernstein’s low-carbohydrate dietary approach. Participants
were instructed to use as much insulin as needed to control blood sugar, and as
a result, adverse outcomes occurred such as increased obesity and suboptimal
glycemic control. On the other hand, the DCCT vindicated Bernstein’s then
controversial assertion that tight blood sugar monitoring and improved glycemic
control reduces microvascular complications [7,8].
He published “Diabetes Type II:
Living a Long, Healthy Life through Blood Sugar Normalization” in 1990,
expanding his advocacy for normal blood sugars in individuals with type 2
diabetes (T2D). In this book, he applied his principles of frequent blood
glucose monitoring, a low-carbohydrate diet, and tailored insulin or medication
use for T2D management. In 1997, Dr. Bernstein published “Dr. Bernstein’s
Diabetes Solution: The Complete Guide to Achieving Normal Blood Sugars”, a
comprehensive guide that became a cornerstone for patients and families
managing diabetes. The book detailed his low-carbohydrate diet and insulin
management strategies. Bernstein explicitly adopted the terms “basal” and
“bolus,” reflecting the evolution of insulin therapy and terminology with the
introduction of rapid-acting and long-acting insulin analogs in the 1990s.
Updated editions followed, with the 4th edition released in 2011. He published
“The Diabetes Diet: Dr. Bernstein’s Low-Carbohydrate Solution” in 2005,
focusing specifically on dietary strategies for diabetes management.
The TypeOneGrit Facebook group, which
focuses on individuals with T1D following Dr. Bernstein’s protocol, is one of
the most prominent and well-documented social media groups of its kind. Dr.
Bernstein was co-author of a cross-sectional survey of 316 TypeOneGrit
participants. Bernstein’s protocol was associated with exceptional glycemic
control (near-normal HbA1c), low insulin requirements, and minimal adverse
events in this self-selected T1D cohort [9]. This study supports Bernstein’s
approach and should further influence diabetes research in similar fashion to
Bernstein’s prior work.
Dr. Bernstein met with Tracey Brown,
the American Diabetes Association (ADA) CEO at that time, as was made apparent
in a tweet by Brown herself on February 11th, 2019. Later in the same year, the
ADA officially released its Consensus Report on Nutrition Therapy for Adults
with Diabetes or Prediabetes [10]. This report was the first to recognize that
reducing overall carbohydrate intake has the most evidence for improving
glycemia and recommended low-carbohydrate and very low-carbohydrate diets as
viable options for individuals with T2D.
Dr. Bernstein reflected on his
longevity in “My Life with Diabetes: 69 Years and Counting” on his website in
2015, attributing his survival past the average life expectancy for T1D to his
low-carb diet and glycemic control [1]. He proclaimed that to his knowledge
there were no persons from his diagnosis era diagnosed with T1D that were
without active complications. He continued to practice medicine this year at
age 90, accepting new patients while maintaining good health. In total, he
published 9 books on diabetes management, with his work widely adopted by
patients globally. He passed away peacefully at age 90 [11].
Global diabetes care, notably in
Japan through the Japan Low Carbohydrate Diet Promotion Association (JLCDPA),
has been positively impacted. Dr. Koji Ebe, founder of the JLCDPA in 2013, has
drawn on Bernstein’s methods to educate medical professionals about
low-carbohydrate diets for diabetes therapy [12-14]. Ebe’s efforts focus on
challenging cultural dietary norms, such as reducing high rice consumption, to
promote glycemic control, aligning with Bernstein’s principles. The JLCDPA
prioritizes disseminating accurate, evidence-based information about
low-carbohydrate diets (LCDs) through seminars, workshops, and publications.
This includes hosting regular educational events, such as cooking workshops and
medical seminars, to teach patients and healthcare professionals about the
benefits of LCDs (e.g., super-LCD, standard-LCD, and petite-LCD).
Dr. Richard K. Bernstein’s pioneering
work revolutionized diabetes management, demonstrating that tight blood glucose
control through a low-carbohydrate diet, frequent monitoring, and precise
insulin dosing could prevent and reverse complications in both T1D and T2D.
Overcoming initial skepticism and professional barriers, his
self-experimentation, rigorous studies, and influential publications
legitimized his approach, shaping modern diabetes care. It took two decades and
a large randomized clinical trial in order for SMBG to be recommended in
guidelines for diabetes care. The 2019 ADA recognition of LCDs and the success
of communities like TypeOneGrit underscore his lasting impact. Bernstein’s
legacy endures worldwide through improved patient outcomes and a paradigm shift
toward proactive, individualized diabetes management.
Acknowledgments
This
tribute to Dr. Richard K. Bernstein would not be complete without expressing
deep gratitude to R.D. Dikeman, PhD, his son David Dikeman, and their family
for their tireless dedication to advancing Dr. Bernstein’s vision. Following
David’s diagnosis with type 1 diabetes in 2013, the Dikeman family embraced Dr.
Bernstein’s low-carbohydrate approach, transforming David’s health and
inspiring countless others. Their pivotal role in co-founding TypeOneGrit, a
vibrant Facebook community, has provided a lifeline for thousands of people
with type 1 diabetes, fostering support, education, and advocacy for achieving
normal blood sugars. Additionally, R.D. and David’s production and editing of
Dr. Bernstein’s Diabetes University, a free YouTube series, have made Dr.
Bernstein’s groundbreaking methods accessible to a global audience, empowering
individuals to take control of their diabetes. Their passion, generosity, and
commitment to sharing Dr. Bernstein’s philosophy have left an indelible mark on
the diabetes community, amplifying his legacy and helping countless families
thrive.
2.
Dr.
Bernstein interview part 2. Diaverge. 2016.
4.
Diabetes.co.uk.
Dr. Richard Bernstein: Type 1 diabetes pioneer. 2025.
8.
Kolata
G. Vindication for a diabetes expert. The New York Times. 1993.
11.
Diabetes
pioneer Dr Richard Bernstein passes away at age of 90. London: Diabetes.co.uk;
2025.